IRX2 has been explored in the setting of recurrent or metastatic HNSCC—this multi-cytokine immune-activating agent has demonstrated anti-tumor activity in a Phase IB trial in patients with refractory or metastatic HNSCC. The gene discussed is IRX2; the disease is head and neck squamous cell carcinoma.